Plasminogen

• 

  Subject Areas on Research

  • A colorimetric assay for releasable plasminogen activator. 
  • A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. 
  • Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide. 
  • Acute reduction of lipoprotein(a) by tissue-type plasminogen activator. 
  • Alterations in natural anticoagulant levels during allogeneic bone marrow transplantation: a prospective study in 27 patients. 
  • Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis. 
  • Angiostatin binds ATP synthase on the surface of human endothelial cells. 
  • Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. 
  • Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells. 
  • Binding and endocytosis of alpha 2-macroglobulin-plasmin complexes. 
  • Binding of human plasminogen to basement-membrane (type IV) collagen. 
  • Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro. 
  • Catabolism of streptokinase and polyethylene glycol-streptokinase: evidence for transport of intact forms through the biliary system in the mouse. 
  • Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells. 
  • Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. 
  • Coagulation changes in elective surgery and trauma. 
  • Comparison of plasminogen binding and activation on extracellular matrices produced by vascular smooth muscle and endothelial cells. 
  • Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. 
  • Effect of desialylation on the biological properties of human plasminogen. 
  • Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. 
  • Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. 
  • Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of human plasminogen 2. 
  • Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. 
  • Heparin oligosaccharides enhance tissue-type plasminogen activator: a correlation between oligosaccharide length and stimulation of plasminogen activation. 
  • In vitro biosynthesis of plasminogen in a cell-free system directed by mRNA fractions isolated from monkey liver. 
  • Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. 
  • Ionic modulation of the effects of heparin on plasminogen activation by tissue plasminogen activator: the effects of ionic strength, divalent cations, and chloride. 
  • Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. 
  • Lipoprotein (a): purification and kinetic analysis. 
  • Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. 
  • Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. 
  • Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner. 
  • Mechanism of activation of human plasminogen by the activator complex, streptokinase-plasmin. 
  • Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. 
  • Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. 
  • Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain. 
  • Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from the laminin A chain. 
  • Modulation of tissue plasminogen activator-catalyzed plasminogen activation by synthetic peptides derived from the amino-terminal heparin binding domain of fibronectin. 
  • Molecular abnormalities of human plasminogen isolated from synovial fluid of rheumatoid arthritis patients. 
  • Myelin basic protein stimulates plasminogen activation via tissue plasminogen activator following binding to independent l-lysine-containing domains. 
  • Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. 
  • Obesity-related coagulation changes in pregnancy. 
  • Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding. 
  • Plasminogen acceleration of urokinase thrombolysis. 
  • Plasminogen activation stimulates an increase in intracellular calcium in human synovial fibroblasts. 
  • Plasminogen alleles influence susceptibility to invasive aspergillosis. 
  • Plasminogen structural domains exhibit different functions when associated with cell surface GRP78 or the voltage-dependent anion channel. 
  • Regulation of plasminogen activation by components of the extracellular matrix. 
  • Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. 
  • Sialic acid content of plasminogen 2 glycoforms as a regulator of fibrinolytic activity. Isolation, carbohydrate analysis, and kinetic characterization of six glycoforms of plasminogen. 
  • The biochemistry of haemostasis. 
  • The effect of divalent cations on the conformation and function of human plasminogen. 
  • The effect of plasmin on the subunit structure of human fibrinogen. 
  • The effect of substituted laminin A chain-derived peptides on the conformation and activation kinetics of plasminogen. 
  • The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. 
  • The importance of the preactivation peptide in the two-stage mechanism of human plasminogen activation. 
  • The mechanism of action of angiostatin: can you teach an old dog new tricks? 
  • The role of carbohydrate in the function of human plasminogen: comparison of the protein obtained from molecular cloning and expression in Escherichia coli and COS cells. 
  • The temperature-dependent reaction between alpha 2-macroglobulin and streptokinase-plasmin(ogen) complex. 
  • The voltage-dependent anion channel (VDAC) binds tissue-type plasminogen activator and promotes activation of plasminogen on the cell surface. 
  • The voltage-dependent anion channel is a receptor for plasminogen kringle 5 on human endothelial cells. 
  • Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. 
  • Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. 
  • Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. 
  • Why is lipoprotein(a) relevant to thrombosis?